Summary
This 2022 ACC/AHA joint guideline synthesises evidence through systematic review of literature from January 2021 to June 2022 to provide comprehensive recommendations for the diagnosis, evaluation, and management of aortic disease. The guideline updates prior guidance on thoracic aortic disease, peripheral artery disease, and bicuspid aortic valve disease, with new emphasis on shared decision-making, pregnancy-related considerations, and the importance of institutional expertise and multidisciplinary team approaches in patient care.
UK applicability
Whilst published by American organisations, the clinical evidence base and diagnostic/management principles are applicable to UK practice, though UK practitioners would refer to corresponding National Institute for Health and Care Excellence (NICE) guidance and local institutional protocols. The emphasis on multidisciplinary aortic teams and institutional volume thresholds aligns with UK NHS best-practice recommendations for complex cardiovascular conditions.
Key measures
Clinical recommendations for aortic disease management across asymptomatic, stable symptomatic, and acute aortic syndrome presentations
Outcomes reported
The guideline provides evidence-based recommendations for diagnosis, genetic evaluation, medical therapy, endovascular and surgical treatment, and long-term surveillance of aortic disease across multiple clinical presentations. It emphasises shared decision-making, institutional volume requirements, and multidisciplinary team expertise in aortic care.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.